A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities

Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% to 30% of breast cancers and various other types of cancers, which plays a vital role in the cancer progression. Monoclonal antibodies targeting Her2 are now used in the clinic to treat Her2 overexpression cancer p...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaoqiong, Chen, Siqi, Lin, Limin, Liu, Jiayu, Wang, Yanlan, Li, Yumei, Li, Qing, Wang, Zhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852409/
https://www.ncbi.nlm.nih.gov/pubmed/29455083
http://dx.doi.org/10.1016/j.tranon.2018.01.024
_version_ 1783306565698191360
author Wu, Xiaoqiong
Chen, Siqi
Lin, Limin
Liu, Jiayu
Wang, Yanlan
Li, Yumei
Li, Qing
Wang, Zhong
author_facet Wu, Xiaoqiong
Chen, Siqi
Lin, Limin
Liu, Jiayu
Wang, Yanlan
Li, Yumei
Li, Qing
Wang, Zhong
author_sort Wu, Xiaoqiong
collection PubMed
description Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% to 30% of breast cancers and various other types of cancers, which plays a vital role in the cancer progression. Monoclonal antibodies targeting Her2 are now used in the clinic to treat Her2 overexpression cancer patients. However, relapse or resistance is frequent with the current therapies. To generate a new treatment avenue against Her2, we immunized and selected a specific anti-Her2 single domain antibody C3 for further studies. The C3-Fc antibody drove antibody-dependent cell-mediated cytotoxicity against Her2-positive tumor cells in vitro and resulted in potent antitumor growth in vivo. These data suggest that the C3-Fc antibody may provide an alternative avenue for Her2-positive cancer therapy.
format Online
Article
Text
id pubmed-5852409
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-58524092018-03-16 A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities Wu, Xiaoqiong Chen, Siqi Lin, Limin Liu, Jiayu Wang, Yanlan Li, Yumei Li, Qing Wang, Zhong Transl Oncol Original article Human epidermal growth factor receptor 2 (HER2) is overexpressed in approximately 20% to 30% of breast cancers and various other types of cancers, which plays a vital role in the cancer progression. Monoclonal antibodies targeting Her2 are now used in the clinic to treat Her2 overexpression cancer patients. However, relapse or resistance is frequent with the current therapies. To generate a new treatment avenue against Her2, we immunized and selected a specific anti-Her2 single domain antibody C3 for further studies. The C3-Fc antibody drove antibody-dependent cell-mediated cytotoxicity against Her2-positive tumor cells in vitro and resulted in potent antitumor growth in vivo. These data suggest that the C3-Fc antibody may provide an alternative avenue for Her2-positive cancer therapy. Neoplasia Press 2018-02-20 /pmc/articles/PMC5852409/ /pubmed/29455083 http://dx.doi.org/10.1016/j.tranon.2018.01.024 Text en © 2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Wu, Xiaoqiong
Chen, Siqi
Lin, Limin
Liu, Jiayu
Wang, Yanlan
Li, Yumei
Li, Qing
Wang, Zhong
A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
title A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
title_full A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
title_fullStr A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
title_full_unstemmed A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
title_short A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities
title_sort single domain–based anti-her2 antibody has potent antitumor activities
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5852409/
https://www.ncbi.nlm.nih.gov/pubmed/29455083
http://dx.doi.org/10.1016/j.tranon.2018.01.024
work_keys_str_mv AT wuxiaoqiong asingledomainbasedantiher2antibodyhaspotentantitumoractivities
AT chensiqi asingledomainbasedantiher2antibodyhaspotentantitumoractivities
AT linlimin asingledomainbasedantiher2antibodyhaspotentantitumoractivities
AT liujiayu asingledomainbasedantiher2antibodyhaspotentantitumoractivities
AT wangyanlan asingledomainbasedantiher2antibodyhaspotentantitumoractivities
AT liyumei asingledomainbasedantiher2antibodyhaspotentantitumoractivities
AT liqing asingledomainbasedantiher2antibodyhaspotentantitumoractivities
AT wangzhong asingledomainbasedantiher2antibodyhaspotentantitumoractivities
AT wuxiaoqiong singledomainbasedantiher2antibodyhaspotentantitumoractivities
AT chensiqi singledomainbasedantiher2antibodyhaspotentantitumoractivities
AT linlimin singledomainbasedantiher2antibodyhaspotentantitumoractivities
AT liujiayu singledomainbasedantiher2antibodyhaspotentantitumoractivities
AT wangyanlan singledomainbasedantiher2antibodyhaspotentantitumoractivities
AT liyumei singledomainbasedantiher2antibodyhaspotentantitumoractivities
AT liqing singledomainbasedantiher2antibodyhaspotentantitumoractivities
AT wangzhong singledomainbasedantiher2antibodyhaspotentantitumoractivities

Ejemplares similares